Effect of bryostatin 1 on taxol-induced apoptosis and cytotoxicity in human leukemia cells (U937)

Biochemical Pharmacology

Volumn 56, Issue 5, 1998, Pages 635-644

  Wang, Shujie ^a   Guo, Cheng Ye ^a   Castillo, Anthony ^a   Dent, Paul ^a   Grant, Steven ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; Bcl 2; Bryostatin 1; Leukemic cells; Taxol

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; BRYOSTATIN 1; PACLITAXEL;

AGAR GEL ELECTROPHORESIS; APOPTOSIS; ARTICLE; CLONOGENESIS; CONTROLLED STUDY; CYTOTOXICITY; HUMAN; HUMAN CELL; LEUKEMIA CELL; PRIORITY JOURNAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL SURVIVAL; DRUG SYNERGISM; HUMANS; LACTONES; LEUKEMIA, MONOCYTIC, CHRONIC; MACROLIDES; PACLITAXEL; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-BCL-2; U937 CELLS;

EID: 0032169905     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(98)00188-9     Document Type: Article

References (48)

1. Rowinsky E.K. Update on the antitumor activity of paclitaxel in clinical trials. Ann Pharmacother. 28:1993;S18-S22.
2. Rowinski E.K., Onetto N., Canetta R.M., Arbuck S.G. Taxol The first of the taxanes, an important new class of antitumor agents . Semin Oncol. 18:1992;646-662.
3. Kumar N. Taxol-induced polymerization of purified tubulin. Mechanism of action. J Biol Chem. 256:1981;10435-10441.
4. Manfredi J.J., Horwitz S.B. Taxol An antimitotic agent with a new mechanism of action . Pharmacol Ther. 25:1984;83-125.
5. Bhalla K., Ibrado A.M., Tourkina E., Tang C.Q., Mahoney M.E., Huang Y. Taxol induces internucleosomal DNA fragmentation associated with programmed cell death in human myeloid leukemia cells. Leukemia. 7:1993;563-568.
6. cdc2 activation required for apoptosis. Science. 263:1994;1143-1145.
7. Haldar S., Nilamani J., Croce C.M. Inactivation of Bcl-2 by phosphorylation. Proc Natl Acad Sci USA. 92:1995;4507-4511.
8. Blagosklonny M.V., Giannakakou P., El-Deiry W.S., Kingston D.G.I., Higgs P.I., Neckers L., Fojo T. Raf-1/bcl-2 phosphorylation A step from microtubule damage to cell death . Cancer Res. 57:1997;130-135.
9. Haldar S., Chintapalli J., Croce C.M. Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res. 56:1996;1253-1255.
10. Schandl C.A., Priest D.G., Willingham M.C. Phosphorylation of BCL-2 is a cell cycle-regulated event. Cell Pharmacol. 3:1996;367-372.
11. Nishizuka Y. Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. Science. 258:1992;607-614.
12. Kraft A.S., Smith J.B., Berkow R.L. Bryostatin, an activator of the calcium phospholipid-dependent protein kinase, blocks phorbol ester-induced differentiation of human promyelocytic leukemia cells HL-60. Proc Natl Acad Sci USA. 83:1986;1334-1338.
13. Szallasi Z., Smith C.B., Pettit G.R., Blumberg P.M. Differential regulation of protein kinase C isozymes by bryostatin 1 and phorbol 12-myristate 13-acetate in NIH 3T3 fibroblasts. J Biol Chem. 269:1994;2118-2124.
14. II-protein kinase C to the nucleus of human promyelocytic (HL-60) leukemia cells. J Biol Chem. 266:1991;28-33.
15. Lilly M., Brown C., Pettit G., Kraft A. Bryostatin 1 A potential anti-leukemic agent for chronic myelomonocytic leukemia . Leukemia. 5:1991;283-287.
16. Hornung R.L., Pearson J.W., Beckwith M., Longo D.L. Preclinical evaluation of bryostatin as an anticancer agent against several murine tumor cell lines In vitro versus in vivo activity . Cancer Res. 52:1992;101-107.
17. Scheid C., Prendiville J., Jayson G., Crowther D., Fox B., Pettit G.R., Stern P.L. Immunomodulation in patients receiving intravenous bryostatin 1 in a phase I clinical study Comparison with effects of bryostatin 1 on lymphocyte function in vitro . Cancer Immunol Immunother. 39:1994;223-230.
18. Grant S., Jarvis W.D., Swerdlow P.S., Turner A.J., Traylor R.S., Wallace H.J., Lin P.-S., Pettit G.R., Gewirtz D.A. Potentiation of the activity of 1-β-D-arabinofuranosylcytosine by the protein kinase C activator bryostatin 1 in HL-60 cells. Association with enhanced fragmentation of mature DNA. Cancer Res. 52:1992;6270-6278.
19. Jarvis W.D., Gewirtz D., Povirk L., Turner A., Traylor R., Pettit G.R., Grant S. Effect of bryostatin 1 and other activators of protein kinase C on 1-β-D-arabinofuranosylcytosine-induced apoptosis in HL-60 human promyelocytic leukemia cells. Biochem Pharmacol. 47:1994;839-852.
20. Grant S., Turner A., Freemerman A., Wang J., Kramer L., Jarvis W.D. Modulation of PKC activity and calcium-sensitive isoform expression in human myeloid leukemia cells Relationship to differentiation and ara-C-induced apoptosis . Exp Cell Res. 228:1996;65-75.
21. Huang Y., Waxman S. Enhanced apoptosis in leukemia cells following treatment with combination fluoropyrimidines and differentiation inducers. Mol Cell Differ. 2:1994;83-100.
22. 3 correlates with the rate of maturation of DNA replication intermediates. Cancer Res. 51:1991;3451-3455.
23. Bhatia U., Traganos F., Darzynkciewicz Z. Induction of cell differentiation potentiates apoptosis triggered by prior exposure to DNA-damaging agents. Cell Growth Differ. 6:1995;937-944.
24. May W.S., Tyler P.G., Ito T., Armstrong D.K., Qatsha K.A., Davidson N.E. Interleukin-3 and bryostatin-1 mediate hyperphosphorylation of BCL-2α in association with apoptosis. J Biol Chem. 269:1994;26865-26870.
25. Wang S., Vrana J.A., Bartimole T., Freemerman A.J., Jarvis W.D., Kramer L.B., Krystal G., Dent P., Grant S. Agents that down-regulate or inhibit protein kinase C circumvent resistance to 1-β-D-arabinofuranosylcytosine-induced apoptosis in human leukemia cells overexpressing Bcl-2. Mol Pharmacol. 52:1997;1000-1009.
26. Ibrado A.M., Liu L., Bhalla K. Bcl-xL overexpression inhibits progression of molecular events leading to paclitaxel-induced apoptosis of human acute myeloid leukemia. Cancer Res. 52:1997;1109-1115.
27. WAF1 and p53 requires c-raf-1. Cancer Res. 55:1995;4623-4626.
28. Chou T.C., Talalay P. Quantitative analysis of dose-effect relationships The combined effects of multiple drugs or enzyme inhibitors . Adv Enzyme Regul. 22:1984;27-55.
29. Scala S., Dickstein B., Regis J., Szallasi Z., Blumberg P.M., Bates S.E. Bryostatin 1 affect P-glycoprotein phosphorylation but not function in multidrug-resistant human breast cancer cells. Clin Cancer Res. 1:1995;1581-1587.
30. Pumiglia K.M., Decker S.J. Cell cycle arrest mediated by the MEK/mitogen-activated protein kinase pathway. Proc Natl Acad Sci USA. 94:1997;448-452.
31. Asiedu C., Biggs J., Lilly M., Kraft A.S. Inhibition of leukemic cell growth by the protein kinase C activator bryostatin 1 correlates with the dephosphorylation of cyclin-dependent kinase 2. Cancer Res. 55:1995;3716-3720.
32. Vrana J., Saunders A.M., Chellapan S.P., Grant S. Divergent effects of bryostatin 1 and PMA on cell cycle arrest and maturation in human myelomonocytic leukemia cells (U937). Differentiation. 63:1998;33-42.
33. Solary E., Bertrand R., Pommier Y. Differential induction of apoptosis in differentiating HL-60 cells to apoptosis by DNA topoisomerase inhibitors. Blood. 81:1993;1359-1368.
34. Yin D.X., Schimke R.T. BCL-2 expression delays drug-induced apoptosis but does not increase clonogenic survival after drug treatment in HeLa cells. Cancer Res. 55:1995;4922-4928.
35. Lock R.B., Stribinskience L. Dual modes of cell death induced by etoposide in human epithelial tumor cells allow Bcl-2 to inhibit apoptosis without affecting clonogenic survival. Cancer Res. 56:1996;4006-4012.
36. Huang Y., Ibrado A.M., Reed J.C., Bullock G., Ray S., Tang C., Bhalla K. Co-expression of several molecular mechanisms of multidrug resistance and their significance for paclitaxel cytotoxicity in human AML HL-60 cells. Leukemia. 11:1997;253-257.
37. Oltavi Z.N., Milliman C., Korsmeyer S. Bcl-2 heterodimerized in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell. 74:1993;609-619.
38. Yang J., Liu X., Bhalla K., Kim C.N., Ibrado A.M., Cai J., Peng T.-I., Jones D.P., Wang X. Prevention of apoptosis by Bcl-2 Release of cytochrome c from mitochondria blocked . Science. 275:1997;1129-1132.
39. Blagosklonny M.V., Schulte T., Nguyen P., Trepel J., Neckers L.M. Taxol-induced apoptosis and phosphorylation of Bcl-2 protein involves c-Raf-1 and represents a novel c-Raf-1 signal transduction pathway. Cancer Res. 56:1996;1851-1854.
40. Ito T., Deng X., Carr B., May W.S. Bcl-2 phosphorylation required for anti-apoptosis function. J Biol Chem. 272:1997;11671-11673.
41. Waf1/Cip1 and retinoblastoma protein during okadaic acid-induced apoptosis is coupled with induction of Bax protein in human breast carcinoma cells. Cell Growth Differ. 7:1996;1599-1607.
42. Grant S., Turner A., Bartimole T.M., Nelms P., Joe V., Jarvis W.D. Modulation of 1-β-D-arabinofuranosylcytosine-induced apoptosis in human promyelocytic leukemia cells by staurosporine and other inhibitors of protein kinase C. Oncol Res. 6:1994;87-99.
43. Lee H.-W., Smith L., Pettit G.R., Vinitsky A., Smith J.B. Ubiquitination of protein kinase C-α and degradation by the proteasome. J Biol Chem. 271:1996;20973-20976.
44. Ponnathpur V., Ibrado A.M., Reed J.C., Ray S., Huang Y., Self S., Bullock G., Nawabi A., Bhalla K. Effects of modulators of protein kinases on taxol-induced apoptosis of human leukemic cells possessing disparate levels of p26BCL-2 protein. Clin Cancer Res. 1:1995;1399-1406.
45. Xia Z., Dickens M., Raingeaud J., Davis R.J., Greenberg M.E. Opposing effects of ERK and JNK p38 MAP kinases on apoptosis. Science. 270:1995;1326-1331.
46. Jarvis W.D., Fornari F.A., Auer K.L., Freemerman A.J., Szabo E., Birrer M.J., Johnson C.R., Barbour S.E., Dent P., Grant S. Coordinate regulation of stress- and mitogen-activated protein kinases in the apoptotic actions of ceramide and sphingosine. Mol Pharmacol. 52:1997;935-947.
47. Cai H., Smola U., Wixler V., Eisenmann-Tappe I., Diaz-Meco M.T., Moscat J., Rapp U., Cooper G.M. Role of diglycerol-regulated protein kinase C isotypes in growth factor activation of the Raf-1 protein kinase. Mol Cell Biol. 17:1997;732-741.
48. Wang C.-Y., Mayo M.W., Baldwin A.S. Jr. TNF- and cancer therapy-induced apoptosis Potentiation by NF-κB . Science. 274:1996;784-787.